BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30381297)

  • 21. Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.
    Sakamoto K; Katayama R; Asaka R; Sakata S; Baba S; Nakasone H; Koike S; Tsuyama N; Dobashi A; Sasaki M; Ichinohasama R; Takakuwa E; Yamazaki R; Takizawa J; Maeda T; Narita M; Izutsu K; Kanda Y; Ohshima K; Takeuchi K
    Leukemia; 2018 Dec; 32(12):2590-2603. PubMed ID: 29795241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.
    Tang Z; Liu L; Borlak J
    Clin Epigenetics; 2023 May; 15(1):89. PubMed ID: 37208732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome.
    Yasuda H; Takaku T; Tomomatsu J; Hosone M; Tanaka H; Komatsu N
    Intern Med; 2014; 53(23):2717-20. PubMed ID: 25447656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Khoury JD
    Curr Hematol Malig Rep; 2018 Dec; 13(6):477-483. PubMed ID: 30350260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Nagate Y; Nakaya A; Kamimura R; Hirose Y; Nojima S; Fujita J; Kiyohara E; Shibayama H
    Intern Med; 2023; 62(17):2547-2551. PubMed ID: 37661416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epigenetic deregulation in myeloid malignancies.
    Huang HT; Figueroa ME
    Blood; 2021 Aug; 138(8):613-624. PubMed ID: 34436526
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.
    Yu J; Qin B; Moyer AM; Nowsheen S; Liu T; Qin S; Zhuang Y; Liu D; Lu SW; Kalari KR; Visscher DW; Copland JA; McLaughlin SA; Moreno-Aspitia A; Northfelt DW; Gray RJ; Lou Z; Suman VJ; Weinshilboum R; Boughey JC; Goetz MP; Wang L
    J Clin Invest; 2018 Jun; 128(6):2376-2388. PubMed ID: 29708513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine.
    Laribi K; Denizon N; Ghnaya H; Atlassi M; Besançon A; Pineau-Vincent F; Gaulard P; Petrella T
    Eur J Haematol; 2014 Jul; 93(1):81-5. PubMed ID: 24571716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA methyltransferase inhibition overcomes diphthamide pathway deficiencies underlying CD123-targeted treatment resistance.
    Togami K; Pastika T; Stephansky J; Ghandi M; Christie AL; Jones KL; Johnson CA; Lindsay RW; Brooks CL; Letai A; Craig JW; Pozdnyakova O; Weinstock DM; Montero J; Aster JC; Johannessen CM; Lane AA
    J Clin Invest; 2019 Nov; 129(11):5005-5019. PubMed ID: 31437130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blastic plasmacytoid dendritic cell neoplasm: evolving insights in an aggressive hematopoietic malignancy with a predilection of skin involvement.
    Gera S; Dekmezian MS; Duvic M; Tschen JA; Vega F; Cho-Vega JH
    Am J Dermatopathol; 2014 Mar; 36(3):244-51. PubMed ID: 24247574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Enhancer hijacking via disease-specific chromosomal translocation in blastic plasmacytoid dendritic cell neoplasm].
    Kubota S
    Rinsho Ketsueki; 2020; 61(1):47-51. PubMed ID: 32023603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients.
    Khanlari M; Yin CC; Takahashi K; Lachowiez C; Tang G; Loghavi S; Bah I; Wang W; Konoplev S; Medeiros LJ; Pemmaraju N; Khoury JD; Wang SA
    Leukemia; 2022 May; 36(5):1343-1350. PubMed ID: 35279700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Kato Y; Egusa C; Maeda T; Tsuboi R
    J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.
    Halaban R; Krauthammer M; Pelizzola M; Cheng E; Kovacs D; Sznol M; Ariyan S; Narayan D; Bacchiocchi A; Molinaro A; Kluger Y; Deng M; Tran N; Zhang W; Picardo M; Enghild JJ
    PLoS One; 2009; 4(2):e4563. PubMed ID: 19234609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
    Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
    J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Demethylation of DNA by decitabine in cancer chemotherapy.
    Brown R; Plumb JA
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):501-10. PubMed ID: 15270655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
    Yokoyama M; Chiba T; Zen Y; Oshima M; Kusakabe Y; Noguchi Y; Yuki K; Koide S; Tara S; Saraya A; Aoyama K; Mimura N; Miyagi S; Inoue M; Wakamatsu T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Yokosuka O; Iwama A
    Oncotarget; 2017 Mar; 8(13):21315-21326. PubMed ID: 28423509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blastic plasmacytoid dendritic cell neoplasm: update on therapy especially novel agents.
    Wang S; Wang X; Liu M; Bai O
    Ann Hematol; 2018 Apr; 97(4):563-572. PubMed ID: 29455234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.